Temozolomide in Radio-chemotherapy Combined Treatment for Newly-diagnosed Glioblastoma Multiforme: Phase II Clinical Trial

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 5159-5164

  Lanzetta, G ^a,b   Campanella, C ^a   Rozzi, A ^a   Nappa, M ^a   Costa, A ^a   Fedele, F ^a   Innocenzi, G ^b   Gagliardi, F M ^b   Salvati, M ^b   Minniti, G ^b   Frati, A ^b   Frati, L ^c   Vecchione, A ^b  

^a Istituto Neurotraumatologico Italiano   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Univ Studi Roma La Sapienza ^*

Author keywords

Glioblastoma multiforme; Radio chemotherapy combined treatment; Temozolomide

Indexed keywords

ALKYLATING AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; CORTICOSTEROID; GADOLINIUM; GRANISETRON; ONDANSETRON; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; INFECTION; LYMPHOCYTOPENIA; MALE; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DOSE FRACTIONATION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED;

EID: 10744221333     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Macdonald DR: Temozolomide for recurrent high-grade glioma. Semin Oncol 28(suppl 13): 3-12, 2001.
2. Stupp R and Newlands E: New approaches for temozolomide therapy: use in newly diagnosed glioma. Semin Oncol 28(13): 19-23, 2001.
3. Forsyth PAJ and Cairincross JG: Chemotherapy for malignant gliomas. Baillieres Clin Neurol 5: 371-93, 1996.
4. Young WK, Prados MD, Yaya-Tur R et al: Multicenter phase-II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762-71, 1999.
5. Yung WK: Temozolomide in malignant gliomas. Semin Oncol 27(suppl 6): 27-34, 2000.
6. Chamberlain MC and Kormanik PA: Practical guidelines for the treatment of malignant gliomas. West J Med 168: 114-20, 1998.
7. Stupp R, Gander M, Leyvraz S, Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2: 552-60, 2001.
8. Newlands ES, O'Reilly SM, Glaser MG et al: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A: 2236-41, 1996.
9. O'Reilly SM, Newlands ES, Glaser MG, Brampton MH, Rice-Edwards JM, Illingworth RD et al: Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A: 940-2(9), 1993.
10. Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, Prados MD et al: A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5): 588-93, 2000.
11. Osoba D, Brada M, Yung WKA et al: Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 36: 1788-95, 2000.
12. Friedman HS: Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin Oncol 27(3, suppl 6): 35-40, 2000.
13. Darkes MJM, Plosker GL, Jarvis B. Temozolomide: A review of its use in the treatment of malignant gliomas, malignant melanoma and other advanced cancers. Am J Cancer 1(1): 55-80, 2002.
14. Wedge SR, Porteous JK, Glaser MG et al: In vitro evaluation of temozolomide combined with irradiation. Anticancer Drugs 8: 92-97, 1997.
15. Steel GG and Peckham MJ: Exploitable mechanism in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91, 1979.
16. Curran WJ Jr, Scott CB, Horton J et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: 704-10, 1993.
17. Fountizilas G, Karavelis A, Capizzello A et al: Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study. J Neurooncol 45(2): 159-65, 1999.
18. Brandes AA, Rigon A, Zampieri P, Ermani M, Carollo C, Altavilla G et al: Carbpolatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. Cancer 82(2): 355-61, 1998.
19. Fisher BJ, Scott C, Macdonald DR et al: Phase I study of topetacan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507. J Clin Oncol 19: 1111-17, 2001.
20. Del Rowe J, Scott C, Werner-Wasik M et al: Single-arm, open-label phase II study intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 18: 1254-59, 2000.
21. Kleinberg L, Grossman SA, Piantadosi S, Zeltman M and Wharam M: The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. Int J Radiat Oncol Biol Phys 44(3): 535-43, 1999.
22. Stupp R, Dietrich PY, Kraljevic SO, Pica A, Maillard I, Maeder P et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375-82, 2002.